You are here

FDA Approves Pegfilgrastim Biosimilar for Cancer

New Drug Reduces Infection in Chemotherapy Patients

The FDA has approved Udenyca (pegfilgrastim-cbqv, Coherus BioSciences, Redwood City, California) for patients with cancer who are receiving myelosuppressive chemotherapy. Pegfilgrastim-cbqv is a leukocyte growth factor designed to reduce infections as indicated by febrile neutropenia.

The drug is contraindicated for patients who have a history of serious allergic reaction to human granulocyte colony-stimulating factors and is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.

The most common adverse reactions associated with pegfilgrastim-cbqv are bone pain and pain in extremities.

Pegfilgrastim-cbqv is Coherus’ first drug to receive approval from the FDA and has also been approved for use in Europe after receiving a favorable response from the European Medicines Agency’s Committee for Human Use in July of this year.

Source: GlobeNewswire, November 5, 2018; Healio.com, November 5, 2018

More Headlines

Zulresso May Alleviate Symptoms for Thousands of Women
Developed for Tumors Resistant to Other TKIs
Daily Use of AHCC Supplement Could Support Immune System, Eliminate HPV
Unique Bio-Identical Hormone Therapy for Treatment of Hot Flashes
High-Tech “Nightwatch” is Capable of Detecting 85 Percent of Severe Night-Time Epileptic Seizures
Combination of Buprenorphine and Samidorphan Targets Opioid System Safely and Effectively
Prevents Harmful Effects of Chemotherapy
New Visualization System for Minimally Invasive Spine Surgery